This Monday, January 8, 2024, the High Authority of Health issued an evaluation of the new saliva test offered by the biotech Ziwig, Endotest, allowing the rapid diagnosis of the disease endometriosis. She indicates that it will be subject to additional studies.
In recent years, the subject of endometriosis has gained more and more space, eventually becoming more popular. Very good news when we know that 10 to 15% of women suffer from it. For many years, endometriosis was not recognized, so many women kept silent about the various ailments that the disease could cause: intense pain in the uterus, hemorrhagic bleeding, pain during sexual intercourse in the lower abdomen, chronic fatigue, digestive disorders, but also pelvic and lower back pain.
Being a disease that has only recently been studied, the diagnosis of endometriosis still remains difficult today. Indeed, it generally requires a clinical examination by a gynecologist accompanied as a first step by a pelvic ultrasound or an MRI, often experienced in a distressing manner by patients. Then as a second intention when the diagnosis could not be made by invasive exploration, laparoscopy which requires general anesthesia. An obstacle course that could be avoided thanks to this new saliva test developed by a Lyon biotech, Endotest.
The rest after this ad
How does the test work and what does HAS say?
This Monday, January 8, the High Authority of Health (HAS) has just published an evaluation of this new saliva test making it possible to diagnose the disease endometriosis. If he was described as “promising» by the body, it will above all make it possible to avoid surgical intervention or even years of examinations for women suffering from the disease, but also for those who are not affected and who find themselves on this course for equivalent symptoms. But then how does it work? The Endotest developed by the company Ziwig only requires a saliva sample (a tube into which you will have to spit) to identify the disease in menstruating women between 18 and 43 years old. The sample is then sequenced at high throughput and then analyzed by artificial intelligence developed by the same company.
If the test had already been studied on 200 patients, a new study was carried out, this time including more than 1000 women presenting symptoms of pelvic pain. Results which convinced the HAS which proposed to launch a package “innovation» which could allow women over 18 years of age for whom the disease is suspected to carry out this test free of charge for some “conditioned» to collaboration on new studies. It remains to be seen whether the government will accept the proposal when we know that the Endotest is already marketed in more than 17 countries around the world, including European countries such as Switzerland.
The people? A whole world! Passionate about the media, networks, series, films, and investigative investigations of all kinds, it was natural that Jessica turned to writing and that she takes…